Sabatolimab

N/A

Report date: 2025/04/25 16:01:51

Base Information

Drug NameSabatolimab
Drug Alias NameMBG-453NVP-MBG453
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionHepatitis A virus cellular receptor 2 inhibitors
TargetsHepatitis A virus cellular receptor 2
Therapy Area/IndicationsPrimary MyelofibrosisMyelodysplastic SyndromesBone Marrow Diseases +[14
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[40
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsBone Marrow DiseasesHematologic DiseasesPreleukemia +[7
Inactive IndicationsPrimary MyelofibrosisMyelodysplastic SyndromesThrombocythemia, Essential +[7

Other Information

ATC CodeN/A
Related LinksN/A